Cargando…
Dyslipidemia in Children Treated with a BRAF Inhibitor for Low-Grade Gliomas: A New Side Effect?
SIMPLE SUMMARY: The use of targeted therapies is revolutionizing the prognosis of many cancers; however, there is still limited knowledge of their side effects. Dyslipidemia is often present in cancer patients due to mechanisms that are directly or indirectly related to cancer or therapies. The aim...
Autores principales: | Crocco, Marco, Verrico, Antonio, Milanaccio, Claudia, Piccolo, Gianluca, De Marco, Patrizia, Gaggero, Gabriele, Iurilli, Valentina, Di Profio, Sonia, Malerba, Federica, Panciroli, Marta, Giordano, Paolo, Calevo, Maria Grazia, Casalini, Emilio, Di Iorgi, Natascia, Garrè, Maria Luisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179293/ https://www.ncbi.nlm.nih.gov/pubmed/35681673 http://dx.doi.org/10.3390/cancers14112693 |
Ejemplares similares
-
LGG-35. Dyslipidemia in children treated with BRAF inhibitors for brain tumor, a new side effect? A single center retrospective study
por: Crocco, Marco, et al.
Publicado: (2022) -
LGG-40. Growth hormone replacement in children on therapy with Vemurafenib for Low Grade Glioma
por: Verrico, Antonio, et al.
Publicado: (2022) -
Case Report: The Emerging Role of Ring Chromosome 22 in Phelan-McDermid Syndrome With Atypical Teratoid/Rhabdoid Tumor: The First Child Treated With Growth Hormone
por: Crocco, Marco, et al.
Publicado: (2021) -
Early molecular diagnosis of BRAF status drives the neurosurgical management in BRAF V600E-mutant pediatric low-grade gliomas: a case report
por: Piccolo, Gianluca, et al.
Publicado: (2022) -
LGG-34. Nephrological impact of BRAF inhibitors in a pediatric population of central nervous system tumors: a single institution experience
por: Verrico, Antonio, et al.
Publicado: (2022)